Novel compounds usable in modulating an activity or function of a voltage-dependent potassium channel and/or of TRPV1 are provided. The compounds are represented by Formula I as described and defined in the specification.

Inter alia, the first titania-catalyzed [.sup.18F]-radiofluorination in highly aqueous medium is provided. In embodiments, the method utilizes titanium dioxide, 1:1 acetonitrile-thexyl alcohol solvent mixture and tetrabutylammonium bicarbonate as a base. Radiolabeling may be directly performed with aqueous [.sup.18F]fluoride without the need for drying/azeotroping step, which reduces radiosynthesis time while keeping high fluoride conversion. The general applicability of the synthetic strategy to the synthesis of the wide range of PET probes from tosylated precursors is demonstrated.

The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

The present disclosure relates to amorphous and crystalline forms of (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoro-quinolin-4-yl) cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

The present disclosure relates to amorphous and crystalline forms of (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoro-quinolin-4-yl) cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

The present invention relates to novel polymorphs of 4-[3-chloro-4-(N′-cyclopropyl ureido) phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate represented by following structural formula-1a and process for preparation thereof. ##STR00001## Further, the present invention relates to an improved process for the preparation of 4-[3-chloro-4-(N′-cyclopropylureido) phenoxy]-7-methoxyquinoline-6-carboxamide compound of formula-1 or its salts and its intermediates thereof.

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##